LMMY on OTC

Exousia Bio, Inc.

Exousia Bio, Inc. is an American educational services company based in St. Petersburg.1 Its shares trade on OTC under the symbol LMMY.1

Price unavailable

Last updated Oct 21, 2026.

Overview

$3.8KRevenue, fiscal 20252
$51.4KNet income, fiscal 20252

Compare with Rapid Line Inc., Somitos Corp. or Skillful Craftsman Education Technology Ltd, or pick any stock.

  • TickerLMMY on OTC1
  • IndustryServices-Educational Services1
  • HeadquartersSt. Petersburg, Florida1
  • Incorporated inWY3
  • Business address7901 4Th Street N #23494, St. Petersburg, Fl 337023
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company3

Company’s Registration Statement on Form S-1 was declared effective by the Securities and Exchange Commission on February 13, 2023.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-93.4%Gross margin2
1370.5%Net margin2
-67.4%Revenue growth, 20252

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue12¢$7.3K
  • Profit88¢$51.4K

Out of $3.8K in revenue.2

Financial statements

Revenue52$3.8K in 2025
0$5.0K$10.0K$15.0K2023: $0$020232024: $11.5K$11.5K20242025: $3.8K$3.8K2025−67%
Gross profit52-$3.5K in 2025
-$4.0K-$2.0K0$2.0K2023: $0$020232024: $1.8K$1.8K20242025: -$3.5K-$3.5K2025
Net income52$51.4K in 2025
-$100.0K-$50.0K0$50.0K$100.0K2023: -$56.4K-$56.4K20232024: -$25.8K-$25.8K2024−54%2025: $51.4K$51.4K2025

Every line of the income statement as filed: the last 2 fiscal years, latest first.2

Period ending2025-05-312024-05-31
Revenue$3.8K$11.5K
Cost of revenue$7.3K$9.7K
Gross Profit / (loss)-$3.5K$1.8K
Impairment Expenses$3.5K$0
General and administrative expenses$28.4K$28.1K
Total Operating expenses$31.8K$28.1K
Other Income$86.7K$436
Income (Loss) before provision for income taxes$51.4K-$25.8K
Provision for income taxes$0$0
Net income / (loss)$51.4K-$25.8K
Earnings Per Share, Basic$0.00$0.00
Earnings Per Share, Diluted$0.00$0.00
Weighted Average Number of Shares Outstanding, Basic7.8M shares7.8M shares
Weighted Average Number of Shares Outstanding, Diluted7.8M shares7.8M shares

Compare Exousia Bio, Inc. with another company

What it owns

What Exousia Bio, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$02 May 31, 2025$5.0K2 May 31, 2024−100.0%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$02 May 31, 2025$9.5K2 May 31, 2024−100.0%

Properties, in its own words

Our executive offices, which we lease, are located at 201 Allen Street Unit 10104 New York, New York 10002. This office will satisfy our needs for the foreseeable future.

Item 2 of the 10-K filed Oct 17, 2025.4

Former names

  • LAMYAug 29, 2024 to Jan 15, 20263
  • L A M YJul 27, 2022 to Apr 15, 20243

Timeline

  1. Nov 17, 20258-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares10
  2. Dec 17, 20248-K Change in control; Executive or director change11
  3. Aug 29, 20248-K Change of auditor12
  4. Mar 17, 20238-K Executive or director change13

Filings

50 filings to the SEC since October 2021: 4 annual reports, 10 quarterly reports, 4 major events, 32 other. The latest 20:

  1. Aug 31, 202615-12G TERMINATION OF REGISTRATION STMT EDGAR
  2. Jun 16, 202610-Q QUARTERLY REPORT FOR FEB 2026 EDGAR
  3. Apr 14, 2026NT 10-Q EXTENSION EDGAR
  4. Mar 17, 202610-Q FORM 10-Q FOR NOV 2025 EDGAR
  5. Jan 15, 2026NT 10-Q EXTENSION EDGAR
  6. Nov 17, 20258-K EDGAR
  7. Nov 17, 202510-Q EDGAR
  8. Oct 17, 202510-K ANNUAL REPORT EDGAR
  9. Oct 16, 2025NT 10-Q EXTENSION EDGAR
  10. Aug 29, 2025NT 10-K EXTENSION EDGAR
  11. Apr 24, 202510-Q EDGAR
  12. Apr 14, 2025NT 10-Q EXTENSION EDGAR
  13. Jan 10, 202510-Q FORM 10-Q FOR NOV 2024 EDGAR
  14. Dec 17, 20248-K EDGAR
  15. Oct 11, 202410-Q QUARTERLY REPORT EDGAR
  16. Aug 30, 202410-K ANNUAL REPORT EDGAR
  17. Aug 30, 2024NT 10-K FORM 12B-25 EDGAR
  18. Aug 29, 20248-K EDGAR
  19. Apr 15, 202410-Q FORM 10-Q FOR 2-29-24 EDGAR
  20. Jan 16, 202410-Q FORM 10-Q FOR PERIOD ENDING 11/30/23 EDGAR

The 50 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

SEC filer profile

How Exousia Bio, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARExousia Bio, Inc.1
  • CIK0001939937
  • Employer ID (EIN)37-20392164
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inWyoming4
  • Fiscal year endsMay 311
  • Industry code (SIC)8200 Services-Educational Services1
  • SEC reviewing officeOffice of Trade & Services, Division of Corporation Finance1
  • Business address7901 4Th Street N #23494, St. Petersburg, FL 337021
  • Phone940-367-61541
  • Shares outstanding52,500,000 as of Jun 15, 20269
  • Public float$1.3M as of Nov 30, 20244
  • AuditorBOLADALE LAWAL & CO., Lagos, Nigeria PCAOB ID 69934
  • On EDGAR sinceJul 27, 20221
  • Filings50 in all: 10-Q (10), CORRESP (8), S-1/A (7), UPLOAD (7), 8-K (4), NT 10-Q (4), 10-K (3), NT 10-K (2)1
    All 13 form types

    10-K/A (1), 15-12G (1), 8-A12G (1), EFFECT (1), S-1 (1)

  • Latest filingsAnnual report (10-K) Oct 17, 2025
    Quarterly report (10-Q) Jun 16, 2026
    Latest 8-K (8-K) Nov 17, 2025

Securities registered for trading

ClassSymbolExchange
Common Stock

From the cover page of the 10-K filed Oct 17, 2025 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

Legal proceedings

We are not subject to any material legal proceedings, nor, to our knowledge, is any material legal proceeding threatened against us or any of our officers or directors.

The opening of Item 3, Legal Proceedings.4